Bellerophon brings inhaled nitric oxide into Ph2 pulmonary hypertension trial
Bellerophon Therapeutics (NSDQ:BLPH) has enrolled the first patient in a Phase IIb study assessing its INOpulse device in patients with pulmonary hypertension due to interstitial lung disease. The company’s placebo-controlled study is slated to evaluate the safety and efficacy of pulsed, inhaled nitric oxide in patients with PH-ILD, including those with idiopathic pulmonary fibrosis, Bellerophon reported. Get the full story at out sister site, Drug Delivery Business News. The post Bellerophon brings inhaled nitric oxide into Ph2 pulmonary hypertension trial appeared first on MassDevice.
Conditions: Interstitial Lung Disease; Pulmonary Hypertension Intervention: Diagnostic Test: Pulmonary function test Sponsor: Assiut University Completed
This article is protected by copyright. All rights reserved.
ABSTRACT Background and objectiveIn interstitial lung disease (ILD), pulmonary hypertension (PH) is a major adverse prognostic determinant. Transthoracic echocardiography (TTE) is the most widely used tool when screening for PH, although discordance between TTE and right heart catheter (RHC) measured pulmonary haemodynamics is increasingly recognized. We evaluated the predictive utility of the updated European Society of Cardiology/European Respiratory Society (ESC/ERS) TTE screening recommendations against RHC testing in a large, well‐characterized ILD cohort. MethodsTwo hundred and sixty‐five consecutive patients wit...
ConclusionOur findings indicate that the reported association between CPFE and PHT is explained by the summed baseline CT extents of ILD and emphysema. Once baseline severity is taken into account, CPFE is not selectively associated with a malignant microvascular phenotype, when compared with IPF patients without emphysema.
Conclusions: these limited preliminary data seem to suggest that randomized long-term trials with specific drugs are needed in group 3 PH, preferentially addressing patients with severe PH associated to COPD/E.
Conclusion: CT-derived measures of dPA and dPA/dAo should not be used to screen for PH in this population.
Background: Pulmonary hypertension (PH) is a common disorder among patients with interstitial lung diseases (ILDs). The symptoms are usually nonspecific and overlooked among those patients. Thus, using a noninvasive screening modality is recommended for early detection of PH, which has a significant impact on treatment strategy and clinical outcomes.Objectives: To evaluate the ability of forced vital capacity (FVC %)/ diffusion capacity of the lung for carbon monoxide (DLCO %), ratio in prediction of pulmonary hypertension among patients with interstitial lung diseases (ILDs).Patients &Methods: This retrospective study...
Conclusion: CC was frequent among patients with SSc-ILD but was not associated with increased mortality. As expected, PH was associated with severe excess mortality.